secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dogwood Therapeutics, Inc. (DWTX)
CIK:        0001818844
Form:       8-K
Filed at:   2023-04-13T23:59:59+00:00
Accession:  0001558370-23-005868
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Virios reports constructive FDA meeting for IMC-1 fibromyalgia; Long-COVID data expected June 2023
--------------------------------------------------------------------------------

- End-of-Phase 2 FDA meeting for IMC-1 was constructive; Company seeks guidance to advance to Phase 3.
- IMC-1 has been granted FDA Fast Track designation for fibromyalgia.
- Topline results from IMC-2 Long-COVID trial (valacyclovir/celecoxib) expected in June 2023.
- Company believes existing capital supports general and administrative operations into Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818844/000155837023005868/0001558370-23-005868-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818844/000155837023005868/tmb-20230413x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-005868

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer